{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:30:58Z","timestamp":1788582658655,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tianjin Key Medical Discipline Construction Project","award":["Grant N0.TJYXZDXK-3-014B"],"award-info":[{"award-number":["Grant N0.TJYXZDXK-3-014B"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Anti leucine rich glioma inactivated 1 (LGI1)- associated autoimmune encephalitis (AE) is the common form of AE, The treatments for AE may cause many adverse effects and some treatments rely on limited blood resources. Monoclonal antibodies directed against neonatal crystallizable fragment receptor (FcRn), efgartigimod, accelerate autoantibody degradation by blocking IgG recirculation. The efficacy of efgartigimod has been demonstrated in myasthenia gravis. However, there are few case reports on the treatment of anti-LGI1-associated AE with efgartigimod. In this study, we present the case of a patient with anti-LGI1-associated AE who was treated with efgartigimod successfully.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 64-year-old female patient presented with decline in short-term memory and limb tremor. Cranial magnetic resonance imaging (MRI) scan showed hyperintensity and swelling in the medial aspect of the right temporal-occipital lobe on T2- and FLAIR-weighted sequences, without obvious enhancement lesions. The anti-LGI1 antibody titer in serum and CSF was positive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was diagnosed with anti-LGI1-associated AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Initially, the patient received methylprednisolone pulse therapy. Levetiracetam and oxcarbazepine were both administered orally in the meantime. Following treatment failure, efgartigimod was administered once a week for 3 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After treatment, the patient\u2019s limb tremors ceased and her memory improved. The level of anti-LGI1 antibody titer in serum decreased, and the abnormal signals on the MRI attenuated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Efgartigimod is an effective treatment for anti-LGI1-associated AE. This study presents a new approach to treat anti-LGI1-associated AE. However, further research is needed to establish the optimal dosage and frequency of efgartigimod, and to clarify its long-term safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048535","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:01:58Z","timestamp":1778896918000},"page":"e48535","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Successful treatment of anti-LGI1-associated autoimmune encephalitis with efgartigimod: A case report and literature review"],"prefix":"10.1097","volume":"105","author":[{"given":"Rui","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Neurology, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-5441","authenticated-orcid":false,"given":"Guanen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"642078","DOI":"10.3389\/fneur.2021.642078","article-title":"Characteristics and prognosis of autoimmune encephalitis in the East of China: a multi-center study.","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Neurol"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.mcna.2024.09.001","article-title":"Autoimmune encephalitis.","volume":"109","author":"Guasp","year":"2025","journal-title":"Med Clin North Am"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/NDT.S292343","article-title":"Clinical features and long-term outcomes of anti-leucine-rich glioma-inactivated 1 encephalitis: a multi-center study.","volume":"17","author":"Qiao","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan\u2019s syndrome and acquired neuromyotonia.","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor.","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/pathogens12060817","article-title":"Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker.","volume":"12","author":"Zhou","year":"2023","journal-title":"Pathogens"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of guillain-barr\u00e9 syndrome.","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1007\/s10072-024-07678-3","article-title":"Successful treatment with efgartigimod as an add-on therapy in acute attack of anti-AQP4 antibody-positive NMOSD: a case report.","volume":"45","author":"Huang","year":"2024","journal-title":"Neurol Sci"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1007\/s00415-024-12556-1","article-title":"Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.","volume":"271","author":"Zhu","year":"2024","journal-title":"J Neurol"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12883-025-04034-6","article-title":"Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report.","volume":"25","author":"Huang","year":"2025","journal-title":"BMC Neurol"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"1444288","DOI":"10.3389\/fimmu.2024.1444288","article-title":"Case report: rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series.","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","article-title":"Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review.","volume":"46","author":"Xu","year":"2025","journal-title":"Neurol Sci"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1471-4159.2006.03939.x","article-title":"The LGI1\/epitempin gene encodes two protein isoforms differentially expressed in human brain.","volume":"98","author":"Furlan","year":"2006","journal-title":"J Neurochem"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/jvim.12610","article-title":"LGI proteins and epilepsy in human and animals.","volume":"29","author":"Pakozdy","year":"2015","journal-title":"J Vet Intern Med"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00018-021-04088-y","article-title":"The LGI1 protein: molecular structure, physiological functions and disruption-related seizures.","volume":"79","author":"Baudin","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00018-019-03269-0","article-title":"Insights into the mechanisms of epilepsy from structural biology of LGI1-ADAM22.","volume":"77","author":"Yamagata","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"Pt 4","key":"R21-20260904","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/brain\/aww012","article-title":"Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis.","volume":"139","author":"Navarro","year":"2016","journal-title":"Brain"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2019.12.023","article-title":"The exploration of the spectrum of motor manifestations of anti-LGI1 encephalitis beyond FBDS.","volume":"76","author":"Liu","year":"2020","journal-title":"Seizure"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.","volume":"69","author":"Irani","year":"2011","journal-title":"Ann Neurol"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamaneurol.2024.0126","article-title":"Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis.","volume":"81","author":"Kelly","year":"2024","journal-title":"JAMA Neurol"},{"issue":"Pt 10","key":"R25-20260904","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype.","volume":"136","author":"Irani","year":"2013","journal-title":"Brain"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures.","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells.","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R28-20260904","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","article-title":"The B cell immunobiology that underlies CNS autoantibody-mediated diseases.","volume":"16","author":"Sun","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R29-20260904","doi-asserted-by":"crossref","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors.","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J Neurosci"},{"key":"R30-20260904","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/acn3.51847","article-title":"Efficacy of immunotherapy and prognosis in anti-LGI1 encephalitis patients: a meta-analysis.","volume":"10","author":"Kong","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"R31-20260904","doi-asserted-by":"crossref","first-page":"e1088","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry.","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R32-20260904","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2018.00097","article-title":"A new classification system for IgG4 autoantibodies.","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol"},{"key":"R33-20260904","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"R34-20260904","first-page":"100","article-title":"MAPK is implicated in sepsis, immunity, and inflammation.","volume":"8","author":"Saggini","year":"2024","journal-title":"Int J Infect"},{"key":"R35-20260904","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4049\/jimmunol.2100010","article-title":"Activation of transcription factor 4 in dendritic cells controls Th1\/Th17 responses and autoimmune neuroinflammation.","volume":"207","author":"Manoharan","year":"2021","journal-title":"J Immunol"},{"key":"R36-20260904","doi-asserted-by":"crossref","first-page":"103016","DOI":"10.1016\/j.autrev.2021.103016","article-title":"Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases.","volume":"21","author":"Chalayer","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R37-20260904","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses.","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"R38-20260904","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.bbi.2025.01.015","article-title":"Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain.","volume":"125","author":"Fiore","year":"2025","journal-title":"Brain Behav Immun"},{"key":"R39-20260904","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s10753-024-02099-y","article-title":"Methylprednisolone modulates the Tfr\/Tfh ratio in EAE-induced neuroinflammation through the PI3K\/AKT\/FoxO1 and PI3K\/AKT\/mTOR signalling pathways.","volume":"48","author":"Wu","year":"2024","journal-title":"Inflammation"},{"key":"R40-20260904","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.celrep.2018.02.049","article-title":"PI3K\/Akt cooperates with oncogenic notch by inducing nitric oxide-dependent inflammation.","volume":"22","author":"Villegas","year":"2018","journal-title":"Cell Rep"},{"key":"R41-20260904","first-page":"46","article-title":"Inhibition of PI3K\u03b2 and mTOR influence the immune response and the defense mechanism against pathogens.","volume":"7","author":"Avivar-Valderas","year":"2023","journal-title":"Int J Infect"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:02:23Z","timestamp":1788530543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":41,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048535","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2025-08-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}